Géraldine Farjot

Géraldine brings a broad range of expertise needed to translate innovation to patients from bench to bedside, most recently as director of early drug development at Air Liquide Healthcare, where she demonstrated her ability to lead R&D in an open innovation environment, developing strong scientific relationships with preclinical and medical experts in the fields of neurology, respiratory and critical care, bringing assets to the clinical stage with responsibilities ranged from conceptual discovery through toxicology to regulatory affairs, for products in development and approved. Previously, she spent more than a decade at Sanofi as a project leader, where she successfully developed several compounds from early discovery up to early development in the field of metabolic diseases. After a postdoctoral position in cell signaling at the Ludwig Institute for Cancer Research in London, she joined Immutep, during the very early years of this now-successful French biotech company developing immunotherapies.

She holds a Ph.D. in molecular virology from the Ecole Normale Supérieure of Lyon and has authored many publications and patents.